Bumrungrad International Hospital inks MOU with BGI Shenzhen Co. Ltd. and Bangkok Genomics Innovation PLC to strengthen its provision of genomic medicine.

March 20, 2024

Technological advancements in the field of genomics have lowered the cost of human genome sequencing substantially,

Technological advancements in the field of genomics have lowered the cost of human genome sequencing substantially, leading to widespread applications in medicine which have resulted in improved diagnostics and targeted treatments that have in turn saved lives while improving patient quality of life. Particularly, genomic medicine has had a great impact in improving the diagnosis and treatment of rare or hard to diagnose conditions because the field’s body of knowledge has shed important light on the mechanisms by which disease occurs, thus enabling R&D to create targeted treatments and faster more accurate diagnostics. In total, genomic medicine improves how treatments are selected, treatment plans are made, and how early disease can be detected.

Bumrungrad International Hospital, in its role as a leader in global healthcare and a leader in genomic medicine in Thailand, understands the importance of further developing genomics as a field of research and in clinical practice. Hence, Bumrungrad Hospital has chosen to partner with BGI (Shenzhen) Co. Ltd. – a leader in genomics headquartered in the Yantian district of Shenzhen, PRC, and Bangkok Genomics Innovation PLC, a member of BGI Group.

Ms. Artirat Charukitpipat, CEO of Bumrungrad International Hospital, states 
“At Bumrungrad, our mission has always been to provide the highest standard of care, integrating the latest advanced medical technology and research to improve patient outcomes. Genomic medicine offers opportunities to understand diseases at their most fundamental level, tailor treatments to the individuals, and even anticipate health issues before they arise. The objective of having this strategic partnership will bring us closer to a future of predictive and preventative care. Our MOU with BGI is not only a formal agreement but also a commitment to improve the lives of millions of people. It represents a bridge between nations, a fusion of expertise, and a shared vision for a healthier world.”

Assistant Professor Dr. Polakit Teekakirikul, Chief Scientific Officer (Multi-omics) at Bumrungrad Genomic Medicine Institute, adds, “Bumrungrad has been the country’s pioneer in the field of genomics, a commitment underscored by the launch of the Bumrungrad Genomic Institute in February 2023. We are the first to introduce next-generation sequencing (NGS) technology to analyze the decoding of many genes to support personalized and comprehensive care which is the forefront of genomic medicine. Through this collaboration, we can pave the way for a more personalized and precise approach to healthcare, improving patient outcomes and advancing the field of genomics.

Professor Wang Jian, Co-founder and Chairman of the BGI Group Board of Directors, reveals, “We’re honored to share our academic knowledge and research with Bumrungrad. We strongly believe this partnership will contribute to medical research by improving our understanding of genomic technology, and lead to improved treatments. BGI Group looks forward to future collaborations.”
This MOU signing is another significant milestone connecting genomic technology with clinical care. Our goal is to sustainably improve the quality of life and wellbeing of our patients. 







    Scroll for more